FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/02/080659 [Registered on: 17/02/2025] Trial Registered Prospectively
Last Modified On: 04/07/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Other (Specify) [Bumsuit Baby Cream, Lotion, Massage Oil and Shampoo]  
Study Design  Single Arm Study 
Public Title of Study   Testing the Safety of Bumsuit Baby Products for Skin Irritation and Allergies in Healthy Children 
Scientific Title of Study   A Non Randomized, Open Label, Single Center Study to Evaluate the Irritation and Sensitization Potential of Baby Products in Healthy Volunteer Children using Primary Irritation Test.  
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
CTSRS/2427 Version No. 1.0 Dated 11/Dec/2024  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Uday Kumar S 
Designation  Principal Investigator 
Affiliation  Samahitha Research Solutions 
Address  Currex Hospital, No.55-56, Seegehalli Main Road, Bhoo Samartha Layout

Bangalore
KARNATAKA
560059
India 
Phone  06364898825  
Fax    
Email  pi.clinicaltrial@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Ms Sathyavathi L M 
Designation  HOD-Clinical Operations 
Affiliation  Samahitha Research Solutions 
Address  Clinical Research Unit No.1204, Ashva, 2nd Floor, 26th Main, Jayanagar 9th Block, Bangalore Bangalore

Bangalore
KARNATAKA
560069
India 
Phone  9739001749  
Fax    
Email  satyalm@samahitha.com  
 
Details of Contact Person
Public Query
 
Name  Ms Arpita Malgi 
Designation  Team Lead - Clinical Operations 
Affiliation  Samahitha Research Solutions 
Address  Clinical Research Unit No.1204, Ashva, 2nd Floor, 26th Main, Jayanagar 9th Block, Bangalore Bangalore

Bangalore
KARNATAKA
560069
India 
Phone  06364898825  
Fax    
Email  arpita@samahitha.com  
 
Source of Monetary or Material Support  
Kamson Healthcare Pvt. Ltd. Sy.No:546,AA1,AA2, Nandigam ( Village & Mandal) Rangareddy Dist., Telangana,India -509228 
 
Primary Sponsor  
Name  Kamson Healthcare Pvt. Ltd. 
Address  Sy.No:546,AA1,AA2, Nandigam ( Village & Mandal) Rangareddy Dist., Telangana,India -509228 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Uday Kumar S  Currex Hospital  Currex Hospital No.55-56, Seegehalli Main Road, Bhoo Samartha Layout, Seegehalli, KS Halli, Bengaluru
Bangalore
KARNATAKA 
06364898825

pi.clinicaltrial@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Pranav Diabetes Center Ethics Committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  To Evaluate the Irritation and Sensitization Potential of Bumsuit Baby Products in Healthy Volunteer Children using Primary Irritation Test. 
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Bumsuit Baby Cream, Bumsuit Baby Lotion, Bumsuit Baby Massage Oil, and Bumsuit Baby Shampoo  The products will be applied in a patch chamber (0.04 ml) to evaluate skin irritancy and allergic sensitization. The duration of treatment will be 24 hours, with a one-hour window, for a period of 14 days (with an additional one-day window).  
Comparator Agent  NA  NA 
 
Inclusion Criteria  
Age From  5.00 Year(s)
Age To  18.00 Year(s)
Gender  Both 
Details  1. Healthy volunteers aged 5 to 18 years.
2. Subjects with no clinically significant dermatological conditions e.g., eczema, psoriasis.
3. Subjects whose guardians/parents have provided Informed Consent.
4. Willing to adhere to study restrictions no use of other skincare products in the test area.
 
 
ExclusionCriteria 
Details   
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   On-site computer system 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Measurement of local skin reactions such as erythema (redness), edema (swelling), dryness, or scaling at the application site after 24 hours. These will be scored using a standard irritation scoring scale.  Day 0, Day 1, Day 2, Day 3 and Day 7 
 
Secondary Outcome  
Outcome  TimePoints 
Observation of any signs of allergic sensitization, such as delayed erythema, papules, or vesicles, occurring post-24-hour patch removal and in subsequent follow-ups. Sensitization will be scored and categorized based on the intensity of reactions.  Day 0, Day 1, Day 2, Day 3 and Day 7 
 
Target Sample Size   Total Sample Size="24"
Sample Size from India="24" 
Final Enrollment numbers achieved (Total)= "24"
Final Enrollment numbers achieved (India)="24" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   18/02/2025 
Date of Study Completion (India) 28/02/2025 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="0"
Days="7" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

Background and Introduction

The early years are recognized as crucial for children’s healthy development, and proper skincare is considered essential for their long-term well-being. During childhood and adolescence, the skin undergoes several changes, highlighting the need for skincare products to be both safe and effective. Baby products, commonly used to moisturize and protect the skin are to be carefully evaluated to ensure they do not cause irritation or sensitization, particularly since children’s skin is more delicate than that of adults.

Participants with varied skin types were included to determine whether the product is safe for use in children and adolescents. The aim of the study was to provide essential data to confirm the product’s safety, enabling its confident recommendation by parents, caregivers, and healthcare professionals.

Purpose of the Study

The purpose of the study was to evaluate the irritation and sensitization potential of baby products when applied to the skin of healthy children and adolescents aged 5 to 18 years. A primary irritation test was conducted under controlled occlusive conditions to assess the dermatological safety of the products and confirm their suitability for use on sensitive skin. The findings contributed to confirming that the products met safety standards and could be confidently recommended for pediatric use.

Results

The study was conducted over a 7- day period for each participant.A total of 24 healthy children (12 males and 12 females) aged 5 to 18 years were enrolled who successfully completed the study. The average age of participants was 12.9 years. The study assessed four baby care products: Bumsuit Baby Cream, Lotion, Massage Oil, and Shampoo.

Primary Endpoint:
No signs of erythema (redness), edema (swelling), dryness, or peeling were observed in any subject during the study. All participants consistently recorded a score of zero on the Draize scale, confirming that the products were non-irritating and well-tolerated.

Secondary Endpoint:
None of the participants reported sensations of burning, itching, tingling, or other signs of allergic skin reactions. There were no instances of acute or delayed sensitization observed throughout the study period.

Safety Outcomes:
No adverse events (AEs) or serious adverse events (SAEs) were reported. Compliance was 100%, and no protocol deviations or subject withdrawals occurred.

 
Close